{"Clinical Trial ID": "NCT00063570", "Intervention": ["INTERVENTION 1:", "Two-week calendar", "Pemetrexed: 500 mg/m2, intravenous (IV), every 14 days, until disease progression.", "Gemcitabine: 1,500 mg/m2, intravenous (IV), every 14 days, until disease progression.", "INTERVENTION 2:", "21-day calendar", "Pemetrexed: 500 mg/m2, intravenous (IV), every 21 days, until disease progression.", "Gemcitabine: 1000 mg/m2, intravenous (IV) on days 1 and 8 of a 21-day cycle, until disease progression."], "Eligibility": ["Incorporation criteria:", "- Must have received prior chemotherapy with Taxol (pallitaxel) or Taxotere (docetaxel).", "Less than 3 different chemotherapy treatments for metastatic diseases.", "Prior treatment with hormonal treatment and/or radiotherapy.", "There must be a disease that can be measured.", "Must be able to take care of yourself, e.g. personal hygiene", "- Exclusion criteria:", "Do not be pregnant or breast-feeding.", "The cancer that spread to the brain.", "Treatment with Gemcitabine or Pemetrexed", "Could not take folic acid or vitamin B12", "\u2022 Treatment of another cancer in the last 5 years"], "Results": ["Performance measures:", "Overall response of tumours", "The best overall response (confirmed) recorded from the start of treatment to the progression/recurrence of the disease, the start of another therapy/tumour intervention or the end of the trial, whichever occurs first. The response should be confirmed at least 6 weeks after the previous analyses.", "After 6 months, clinical evaluation every 12 weeks and radiological testing as clinically indicated", "Results 1:", "Title of the arm/group: Bi-weekly calendar", "Description arm/group: Pemetrexed: 500 mg/m2, intravenous (IV), every 14 days, until disease progression.", "Gemcitabine: 1,500 mg/m2, intravenous (IV), every 14 days, until disease progression.", "Total number of participants analysed: 52", "Type of measurement: Number", "Unit of measure: Participants Complete response: 2", "Partial reply: 8", "\u2022 Stable disease: 26", "Progressive diseases: 14", "Unknown: 2", "Results 2:", "- Arm/group title: 21 calendar days", "Description arm/group: Pemetrexed: 500 mg/m2, intravenous (IV), every 21 days, until disease progression.", "Gemcitabine: 1000 mg/m2, intravenous (IV) on days 1 and 8 of a 21-day cycle, until disease progression.", "Total number of participants analysed: 21", "Type of measurement: Number", "Unit of measure: Participants Complete response: 0", "Partial reply: 5", "Stable disease: 10", "Progressive diseases: 6", "Unknown: 0"], "Adverse Events": ["Undesirable Events 1:", "Total: 17", "Anemia 2/52 (3.85%)", "- Febrile neutropenia 4/52 (7.69%)", "Pancytopenia 1/52 (1.92%)", "Thrombocytopenia 0/52 (0.00 %)", "Abdominal pain 1/52 (1.92%)", "Constipation 1/52 (1.92%)", "Pyrexia 2/52 (3.85%)", "Hepatic impairment 1/52 (1.92%)", "- Hyperbilirubinaemia 1/52 (1.92%)", "- Device-related infection 1/52 (1.92%)", "Pneumonia 2/52 (3.85%)", "- Sepsis 1/52 (1.92%)", "Adverse Events 2:", "Total: 7", "Anemia 0/21 (0.00 %)", "1/21 (4.76%)", "Pancytopenia 0/21 (0.00 %)", "Thrombocytopenia 1/21 (4.76%)", "Abdominal pain 0/21 (0.00 %)", "Constipation 0/21 (0.00 %)", "Pyrexia 1/21 (4.76 per cent)", "Hepatic impairment 0/21 (0.00 %)", "- Hyperbilirubinaemia 0/21 (0.00 %)", "- Device-related infection 0/21 (0.00 per cent)", "- Pneumonia 0/21 (0.00 %)", "- Sepsis 0/21 (0.00 per cent)"]}